Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T The
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.
| Condition(s) | Relapsed or Refractory Large B-cell Lymphoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma. |
| Who can participate | Inclusion Criteria: * Subject aged ≥ 18 years. * Intended to receive commercial CD19-directed CAR-T cell therapy (axi-cel and liso-cel). * Need for bridging therapy as deemed clinically necessary by the treating physician. * Relapsed or refractory DLBCL, tFL or PMBCL as defined by the 2016 World Health Organization classification (including patients with DLBCL transformed from indolent lymphoma), or high-grade B-cell lymphoma (HGBL), not otherwise specified, and HGBL with MYC and BCL2 and/or BCL6 rearrangements. --Relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) disease following at least one multi-agent systemic treatment regimen. * Measurable disease as defined by the 2014 Lugano Classification as assessed by positr |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Utah |
| Locations | Salt Lake City, Utah, United States |
| Start date | 2025-08-25 |
| NCT ID | NCT06788964 |
| Official listing | https://clinicaltrials.gov/study/NCT06788964 |